COCP — Cocrystal Pharma Cashflow Statement
0.000.00%
- $15.46m
- $5.60m
Annual cashflow statement for Cocrystal Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -9.65 | -14.2 | -38.8 | -18 | -17.5 |
Depreciation | |||||
Non-Cash Items | 0.718 | 0.672 | 19.9 | 0.787 | 0.753 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -1.06 | 0.604 | -2.71 | 2.34 | 0.14 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Cash from Operating Activities | -9.83 | -12.7 | -21.4 | -14.7 | -16.5 |
Capital Expenditures | -0.24 | -0.052 | -0.074 | -0.118 | -0.008 |
Purchase of Fixed Assets | |||||
Cash from Investing Activities | -0.24 | -0.052 | -0.074 | -0.118 | -0.008 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 35.7 | 38.5 | -0.027 | 3.99 | — |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 25.6 | 25.7 | -21.5 | -10.8 | -16.5 |